|
|
News Breaks | | | | September 19, 2012 | | 07:06 EDT |  | GTXI | GTx to present study on Capesarias for prostate cancer
GTx, will make a presentation on the mechanism of action of Capesaris to induce sex hormone binding globulin and subsequently reduce free testosterone in men with castration resistant prostate cancer. GTx CEO Mitchell S. Steiner will present data from the company’s Phase II G200707 clinical study of Capesaris providing evidence that Capesaris increases SHBG, decreases FT, and reduces serum PSA. GTx has initiated a new Phase II clinical trial to evaluate the safety and effectiveness of lower doses of Capesaris to treat men with metastatic castration resistant prostate cancer. The primary endpoint will be to lower serum PSA by ≥ 50% by day 90. | |
|
News For GTXI From The Last 14 Days Check below for free stories on GTXI the last two weeks. |
|
|
| May 22, 2013 | | 11:50 EDT |  | GTXI | High option volume stocks: ZTS AIRM GLDD GTXI MNKD
 Subscribe for More Information | |
|
|
|
|
|
|
